The Medical Letter on Drugs and Therapeutics
Prevention and Treatment of Pertussis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The CDC has reported that many states are experiencing a higher-than-usual incidence of pertussis this year. The highest incidence has been in infants, but the disease has also occurred in older children, adolescents, and adults. Thirteen pertussis-related deaths were reported through August 24; the majority of these were in infants <3 months old.1

VACCINES — The acellular pertussis vaccine now in use produces a shorter duration of immunity than the whole cell pertussis vaccine that was used in the past.2,3 The US Advisory Committee on Immunization Practices (ACIP) now recommends that children receive routine immunization with diphtheria, tetanus toxoid, and acellular pertussis (DTaP) vaccine at 2, 4, 6, and 15-18 months, and again at 4-6 years, for a total of 5 doses.

Adolescents and Adults – Two vaccines ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Prevention and Treatment of Pertussis
Article code: 1399a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian